Farid Takes Helm of Aurion MAB
Aurion Biotech names Marjan Farid chair of medical advisory board
Clinical Scorecard: Farid Takes Helm of Aurion MAB
At a Glance
| Category | Detail |
|---|
| Condition | Corneal Endothelial Disease |
| Key Mechanisms | Progressive vision loss due to corneal endothelial dysfunction |
| Target Population | Patients with corneal endothelial disease, affecting millions globally |
| Care Setting | Clinical settings specializing in ophthalmology and regenerative therapies |
Key Highlights
- Marjan Farid appointed as chair of Aurion's medical advisory board
- Aurion developing AURN001, an investigational allogeneic cell therapy
- Vyznova launched as the first commercially available cell therapy for corneal endothelial disease
- Farid recognized for advancing patient care and innovation in corneal treatments
- Aurion aims to transform corneal care in the United States
Guideline-Based Recommendations
Diagnosis
- Assessment of corneal endothelial function and vision loss
Management
- Consider investigational therapies like AURN001 for eligible patients
Monitoring & Follow-up
- Regular follow-up on visual acuity and corneal health
Risks
- Potential for progressive vision loss if untreated
Patient & Prescribing Data
Individuals diagnosed with corneal endothelial disease
Emerging therapies may offer new hope for vision restoration
Clinical Best Practices
- Integrate advanced treatment options for corneal diseases
- Stay updated on clinical trials and emerging therapies
- Collaborate with specialized centers for complex cases
Related Resources & Content
